mHSPC VL

Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy

Details
Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...

Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...

Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyon...

Details
Whether disease burden in patients with metastatic castration-sensitive prostate cancer (mCSPC) predicts treatment outcomes is unknown. We assessed apalutamide treatment effect in TITAN patients with mCSPC by disease volume, metastasis number and timing of metastasis presentation. Biographies: Axel S. Merseburger, MD, PhD, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany Rela...

Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu

Details
Dingwei Ye introduces a conversation with Alicia Morgans, featuring insights from Professor Yao Zhu, Deputy Executive Director of Urology Surgery at Fudan University Shanghai Cancer Center, on the recent findings from the ARASENS study in the Chinese population. Professor Zhu shares that the study included 202 Chinese patients, about one-seventh of the total, revealing significant efficacy of daro...

ARASENS Phase 3 Clinical Trial Regimen Demonstrates Significant Survival Benefit for Chinese Patients - Yong YANG

Details
Alicia Morgans speaks with Yong YANG about prostate cancer in China, focusing on the ARASENS Phase 3 Clinical Trial. Professor YANG reveals that prostate cancer incidence in China is about 12 per 10,000, with a lower five-year survival rate than in the USA, largely due to late diagnoses. Approximately 60% of patients initially presented with metastasis. Treatment follows international guidelines a...

Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic

Details
Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...

Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard

Details
Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard's work focuses on two main areas: analyzing tumor samples from clinical trials to understand the biology driving cancer aggressiveness and identifying new therapeutic targets. He emphasizes the need for prognostic tests to tailor treatments, especially considering...

Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad

Details
Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels significant...

The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal

Details
Neeraj Agarwal joins Alicia Morgans to discuss the TALAPRO-3 trial, a phase III trial for patients with metastatic hormone-sensitive prostate cancer with DNA repair gene-related alterations or homologous recombination repair gene alterations in the tumors. The trial is ongoing, and accrual is expected to be completed soon. Ultimately, the trial aims to comprehensively assess efficacy, safety, and...

mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad

Details
Alicia Morgans engages with Fred Saad to discuss a network meta-analysis concerning treatments for patients with metastatic hormone-sensitive prostate cancer. They explore the controversies surrounding the most effective treatment for newly diagnosed disease, considering factors like disease volume and whether it's recurrent or de novo. Dr. Saad explains the diminishing role of ADT alone, emphasiz...